Stock Research: Sumitomo Dainippon Pharma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Sumitomo Dainippon Pharma

TSE:4506 JP3495000006
20
  • Value
    1
  • Growth
    86
  • Safety
    Safety
    34
  • Combined
    20
  • Sentiment
    32
  • 360° View
    360° View
    20
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Sumitomo Pharma Co Ltd is a pharmaceutical company. It operates in the pharmaceutical industry and regenerative medicine. The company operates in Japan, North America, and Asia. In the last fiscal year, the company had a market cap of $2729 million, profits of $1637 million, revenue of $2660 million, and 3832 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 20 (better than 20% compared with alternatives), overall professional sentiment and financial characteristics for the stock Sumitomo Dainippon Pharma are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Sumitomo Dainippon Pharma. The consolidated Growth Rank has a good rank of 86, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 86% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 34 means that the share price of Sumitomo Dainippon Pharma is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 66% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 1, which means that the company has a riskier financing structure than 99% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 32, indicating professional investors are more pessimistic about the stock than for 68% of alternative investment opportunities. ...read more

more
Index
Nikkei 225
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
34 30 66 97
Growth
86 88 21 7
Safety
Safety
1 1 1 49
Sentiment
32 14 1 1
360° View
360° View
20 10 4 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
20 1 1 9
Opinions Change
90 82 31 50
Pro Holdings
n/a 26 1 47
Market Pulse
9 5 3 10
Sentiment
32 14 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
34 30 66 97
Growth
86 88 21 7
Safety Safety
1 1 1 49
Combined
20 18 10 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
87 33 97 93
Price vs. Earnings (P/E)
63 91 100 95
Price vs. Book (P/B)
26 31 97 89
Dividend Yield
1 1 1 68
Value
34 30 66 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
86 22 76 9
Profit Growth
91 86 21 30
Capital Growth
1 76 51 8
Stock Returns
100 98 1 57
Growth
86 88 21 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
1 1 5 22
Refinancing
12 1 1 77
Liquidity
18 7 10 51
Safety Safety
1 1 1 49

Similar Stocks

Discover high‑ranked alternatives to Sumitomo Dainippon Pharma and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Daiwabo Holdings

TSE:3107
Country: Japan
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Alfresa Holdings

TSE:2784
Country: Japan
Industry: Health Care Distributors
Size: Large
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.